We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Europe-Japan Diagnostic Study for EGFR Testing (ASSESS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01785888
First Posted: February 7, 2013
Last Update Posted: September 20, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
This is a non-interventional diagnostic, international, multicenter and non-comparative study of EGFR mutation status in aNSCLC patients (locally advanced and/or metastatic disease) with adenocarcinoma and non-adenocarcinoma histologies. This study will be conducted in Japan and Europe and will assess the concordance of EGFR mutation status derived from tumour samples and blood based circulating free DNA. The data generated will inform the use of less-invasive sample types in diagnostic practice. The study also aims to assess the current status of EGFR mutation testing across Japan and Europe and gaps in currently available data including EGFR mutation frequency in particular populations and demographic subgroups, EGFR mutation frequency in histological subtypes of NSCLC, EGFR mutation test process and methodology, utility of multiple sample types in the assessment of EGFR mutation status, and impact of EGFR mutation status on therapy choice. The data may be used to drive improvements to the EGFR mutation testing process, ensuring that patients have access to testing and are treated appropriately on the basis of the molecular features of their disease.

Condition
EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Diagnostic Study of European and Japanese Advanced NSCLC Patients to Evaluate Suitable Sample Types for EGFR Testing,

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Determination of the level of concordance between EGFR mutation status obtained via tissue/cytology and blood (plasma) based testing. [ Time Frame: From randomization until study completion, assessed up to 17 months ]

Secondary Outcome Measures:
  • Determination of the EGFR mutation frequency (including mutation subtypes) in patients with advanced NSCLC (aNSCLC) of adenocarcinoma and non-adenocarcinoma histologies. [ Time Frame: From randomization until study completion, assessed up to 17 months. ]
  • Describe the first line therapy choice following EGFR mutation testing. [ Time Frame: From randomization until study completion, assessed up to 17 months. ]
  • Describe the second line therapy choice following discontinuation of first line treatment for patients confirmed as EGFR mutation positive via tissue/cytology. [ Time Frame: From randomization until study completion, assessed up to 17 months. ]
  • Summary of EGFR mutation testing practices in terms of methods, sample types, success rate, mutation detection rate, testing turnaround time and reasons for not testing. [ Time Frame: From randomization until study completion, assessed up to 17 months. ]
  • Determination of the correlation between EGFR mutation status from tumour and demographic data and disease status. [ Time Frame: From randomization until study completion, assessed up to 17 months. ]
  • Determination of the correlation between EGFR mutation status derived from plasma (blood) and demographic data and disease status. [ Time Frame: From randomization until study completion, assessed up to 17 months. ]

Biospecimen Retention:   Samples With DNA
Tumour samples (biopsy or citology) Blood (plasma) samples

Enrollment: 1311
Study Start Date: April 2013
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
Locally advanced/metastatic NSCLC pts.
Patients(pts.) with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)

Detailed Description:
A diagnostic Study of European and Japanese advanced NSCLC patients to evaluate suitable sample types for EGFR testing,
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
  • Patients with locally advanced (stage IIIA/B) or metastatic NSCLC who are newly diagnosed, have not received any local or systemic chemotherapy. Locally advanced patients should not be eligible for curative treatment (including surgery and chemoradiotherapy).
  • Patients who have newly diagnosed locally advanced (stage IIIA/B) NSCLC who are not eligible for curative treatment (including surgery and chemoradiotherapy) or metastatic NSCLC and have not received systemic chemotherapy. Previous or planned palliative radiotherapy is allowed.
  • Patients who have had surgical resection with or without adjuvant chemotherapy and have experienced recurrent disease.
Criteria

Inclusion Criteria:

  • Patients aged 18 years and older in Europe and aged 20 years and older in Japan
  • Histological or cytological confirmed locally advanced NSCLC (stage IIIA/B) not suitable for curative treatment or metastatic (stage IV) NSCLC.
  • Newly diagnosed patients with locally advanced and/or metastatic NSCLC who are systemic treatment Naïve (i.e. no chemotherapy or EGFR-TKI) or patients with recurrent disease who have previously received adjuvant chemotherapy (not including EGFR-TKI)
  • Provision of diagnostic cancer tissue or cytology sample upon inclusion
  • Provision of a routine blood sample

Exclusion Criteria:

  • Evidence of severe or uncontrolled systemic disease
  • Evidence of any other significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study
  • Pregnancy or breast-feeding
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01785888


  Show 57 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Rose McCormack, PhD AstraZeneca
  More Information

Additional Information:
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01785888     History of Changes
Other Study ID Numbers: D7913C00070
First Submitted: February 4, 2013
First Posted: February 7, 2013
Last Update Posted: September 20, 2016
Last Verified: September 2016

Keywords provided by AstraZeneca:
EGFR,
aNSCLC,
mutation status,
diagnostic study,
Europe,
Japan

Additional relevant MeSH terms:
Adenocarcinoma
Neoplasm Metastasis
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplastic Processes
Pathologic Processes